MA24273A1 - (4-arylthiazol-2yl) sulfonamides et leur utilisation - Google Patents

(4-arylthiazol-2yl) sulfonamides et leur utilisation

Info

Publication number
MA24273A1
MA24273A1 MA24722A MA24722A MA24273A1 MA 24273 A1 MA24273 A1 MA 24273A1 MA 24722 A MA24722 A MA 24722A MA 24722 A MA24722 A MA 24722A MA 24273 A1 MA24273 A1 MA 24273A1
Authority
MA
Morocco
Prior art keywords
arylthiazol
sulfonamides
Prior art date
Application number
MA24722A
Other languages
English (en)
French (fr)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA24273A1 publication Critical patent/MA24273A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/50Nitrogen atoms bound to hetero atoms
    • C07D277/52Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
MA24722A 1996-07-19 1997-07-17 (4-arylthiazol-2yl) sulfonamides et leur utilisation MA24273A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96111661 1996-07-19

Publications (1)

Publication Number Publication Date
MA24273A1 true MA24273A1 (fr) 1998-04-01

Family

ID=8223010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24722A MA24273A1 (fr) 1996-07-19 1997-07-17 (4-arylthiazol-2yl) sulfonamides et leur utilisation

Country Status (23)

Country Link
US (2) US5877193A (en:Method)
EP (1) EP0819681A3 (en:Method)
JP (1) JP2991679B2 (en:Method)
KR (1) KR100247672B1 (en:Method)
CN (1) CN1176101A (en:Method)
AU (1) AU725496B2 (en:Method)
BR (1) BR9704023A (en:Method)
CA (1) CA2210613A1 (en:Method)
CO (1) CO4900053A1 (en:Method)
CZ (1) CZ227397A3 (en:Method)
HR (1) HRP970393A2 (en:Method)
HU (1) HUP9701193A3 (en:Method)
IL (1) IL121298A (en:Method)
MA (1) MA24273A1 (en:Method)
MX (1) MX9705385A (en:Method)
NO (1) NO973338L (en:Method)
NZ (1) NZ328331A (en:Method)
PE (1) PE91298A1 (en:Method)
PL (1) PL321203A1 (en:Method)
SG (1) SG91796A1 (en:Method)
TR (1) TR199700653A2 (en:Method)
YU (1) YU30297A (en:Method)
ZA (1) ZA976222B (en:Method)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725138D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Thiophenesulfonamide compounds
GB9725141D0 (en) * 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
US6211185B1 (en) 1999-05-05 2001-04-03 Veterinary Pharmacy Corporation Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
NZ538100A (en) * 2000-12-13 2006-07-28 Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
WO2005054216A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 新規抗癌剤「スルコキシン」
DK2054397T3 (en) * 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2420494B1 (en) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
US8623347B2 (en) * 2008-01-15 2014-01-07 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2009124086A2 (en) * 2008-04-04 2009-10-08 Siga Technologies, Inc. Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN101602687A (zh) * 2008-06-13 2009-12-16 上海特化医药科技有限公司 6-硝基苯乙酮类化合物、其制备方法及用途
CN106518845B (zh) * 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
CN102627589A (zh) * 2012-04-05 2012-08-08 天津理工大学 一种两步合成制备4-异丙基苯磺酰氯的方法和工艺
CN102633696A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种两步合成制备对位取代烷基苯磺酰氯的方法和工艺
CN102633695A (zh) * 2012-04-05 2012-08-15 天津理工大学 一种4-异丙基苯磺酰氯的制备方法和工艺
CN102633687B (zh) * 2012-04-05 2016-06-08 天津瑞岭化工有限公司 一种对位取代烷基苯磺酰氯的制备方法和工艺
JP6469009B2 (ja) * 2012-09-21 2019-02-13 ロード アイランド ホスピタル がん処置用β−ヒドロキシラーゼ阻害剤
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
MX2019006697A (es) 2016-12-09 2019-08-16 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
WO2019241533A1 (en) 2018-06-13 2019-12-19 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
CN113164419A (zh) * 2018-09-07 2021-07-23 皮克医疗公司 Eif4e抑制剂和其用途
CN114516807B (zh) * 2022-02-24 2023-11-17 南京大学 一种含硝基多取代芳香二胺单体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
WO1996016650A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives

Also Published As

Publication number Publication date
KR980008228A (ko) 1998-04-30
US5877193A (en) 1999-03-02
YU30297A (sh) 2000-10-30
HUP9701193A3 (en) 2000-08-28
AU2875297A (en) 1998-01-29
EP0819681A2 (de) 1998-01-21
KR100247672B1 (ko) 2000-04-01
HUP9701193A2 (hu) 1999-02-01
CN1176101A (zh) 1998-03-18
JP2991679B2 (ja) 1999-12-20
NZ328331A (en) 1999-05-28
PL321203A1 (en) 1998-02-02
NO973338D0 (no) 1997-07-18
HU9701193D0 (en) 1997-09-29
NO973338L (no) 1998-01-20
TR199700653A2 (xx) 1998-02-21
IL121298A (en) 2001-03-19
PE91298A1 (es) 1998-12-31
AU725496B2 (en) 2000-10-12
BR9704023A (pt) 1998-11-17
EP0819681A3 (de) 1998-02-04
CO4900053A1 (es) 2000-03-27
HRP970393A2 (en) 1998-04-30
JPH1067761A (ja) 1998-03-10
ZA976222B (en) 1998-01-19
IL121298A0 (en) 1998-01-04
SG91796A1 (en) 2002-10-15
US5958910A (en) 1999-09-28
MX9705385A (es) 1998-04-30
CZ227397A3 (cs) 1998-02-18
CA2210613A1 (en) 1998-01-19

Similar Documents

Publication Publication Date Title
MA24273A1 (fr) (4-arylthiazol-2yl) sulfonamides et leur utilisation
MA24237A1 (fr) Sulfonamides et leur utilisation.
NO984316D0 (no) Skjµreverkt°y
DE69706890D1 (de) Vorausbezahlte karte
ID15921A (id) Peralatan pengeringan
NO983462D0 (no) Isoleringsverkt°y
DE69720546D1 (de) Kaskadierter Anschluss von kommuniziernden Geräten
ID17873A (id) Penghambat trombin baru
NO990552L (no) Innrettingsverkt°y
EP1012279A4 (en) MITOFUSIN GENES AND THEIR USE
DE69714146D1 (de) Polyether modifizierte Fluoralkylsiloxane
DE69724381D1 (de) Nichtreziproke Schaltungsanordnung
BR9708248A (pt) Benzotiofenos formulações contendo os mesmos e metódos
BR9707657A (pt) Benzotiofenos formulações contendo os mesmos e métodos
FI960994L (fi) Erotuslaite ja siinä olevia komponentteja
IS4998A (is) Flokkunarbúnaður
EP1241257A4 (en) TACHYKININ-SIMILAR POLYPEPTIDES AND ITS APPLICATION
EP1000925A4 (en) TRIPHENYLMETHANE DERIVATIVES AND THEIR USE
FR2757398B1 (fr) Formulation de bambuterol et son utilisation
FR2722198B1 (fr) 1derives de silylmethyl-anilines, le2fabrication, et leur utilisation co
ID16791A (id) Peralatan pengering
DE69736101D1 (de) Y/C-Zweizeilen-Trennvorrichtung
DE69714188D1 (de) Y/C-Trennstufe
KR980000320U (ko) 뺏지 부착용 핀
KR970060741U (ko) 압봉